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Calcineurin inhibitors (CNI), cyclosporin A and tacrolimus, are potent 
immunosuppressive agents but induce toxicity causing damages and graft dysfunction in 
kidney transplant recipients. They also have been suggested to contribute to late-term loss 
of graft, which is depicted by interstitial fibrosis and tubular atrophy (IF/TA). Even with 
emerging insights on mechanism of CNI nephrotoxicity, prevention and treatment of this 
toxicity remain a major clinical challenge due to its low dose-toxicity correlation, a 
difficulty in establishing a differential diagnosis, and varying individual susceptibility. 
We hypothesize that CNI nephrotoxicity follows distinct disease pathways and is 
characterized by significant gene signatures that differentiate it from other conditions. 
Moreover, we postulate that CNI-induced toxicity profiles contribute to the IF/TA 
signatures. 
Microarray analysis and gene annotation were done on the study database 
included of tissues diagnosed with CNI nephrotoxicity (n = 9), interstitial fibrosis/tubular 
  
xi 
atrophy (IF/TA, n=10), and normal function allografts (NFA, n = 8). All samples were 
histologically classified based on the revised Banff  ‘07 criteria for renal allograft 
pathology. Top-scored biological networks in CNI tissues were related to metabolic 
disease, cellular development, renal necrosis, apoptosis cell-death, immunological 
disease, inflammatory disease, and many others. Canonical pathway analysis emphasized 
oxidative stress response mediated by NRF2 and various cell-death signaling pathways 
including 14-3-3 signaling pathway, p53 signaling pathway, and TGF- signaling 
pathway.  
Profiling of characteristic gene expression patterns was done based on their 
statistical significance and biological relevance to the unique pathology of CNI 
nephrotoxicity. Three differentially expressed genes RGS1, CXCR4, and TGIF1, which 
showed good correlation between microarray data and real time-PCR, were validated in 
an independent set of sample tissues. Even though only RGS1 gene expression level was 
statistically significant between CNI group and normal function allograft, relative fold 
changes of both RGS1 and CXCR4 showed a significant up-regulation associated with 
the pathological groups (CNI and IF/TA), when compared to normal function allograft. 
We did not, however, find any association between the expression of TGIF1 in either 
CNI group or IF/TA group.  
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CHAPTER 1: INTRODUCTION 
 
 
I. An Overview of Kidney Transplantation 
1. Prevalence and Current Trends 
To date, approximately 23 million people, more than 11.5% of the U.S. adult 
population, are suffering from chronic kidney disease, with high risk of having kidney 
failure, end-stage renal disease (ESRD), and even mortality (1,2). Kidney transplantation 
has been the therapy of choice for patient with ESRD for decades. Over the past 10 years, 
there is an improvement in short-term patient and graft survival due to advances in 
surgical techniques as well as clinical immunology in transplantation (2). According to a 
study on kidney transplantation in the U.S. from 1999 to 2008, unadjusted patient 
survival rates at 5 years after transplant were 91% for recipients of living donor (LD) 
kidneys, 84% for non-expanded donor criteria deceased donor (non-ECD DD) kidneys, 
and 72% for expanded donor criteria (ECD) kidney transplants (3). Unadjusted graft 
survival at 5 years post-transplantation followed a similar trend with 81% for LD, 72% 
for non-ECD, and 57% for ECD transplants (3).  
Despite this promising short-term outcome, long-term survival rate of kidney 
transplant recipients is poor. One of the main reasons is the growing disparity between 
the number of patients waiting for organs and the number of organs available for 
transplant (4). In fact, 94,293 patients are registered on the national waiting list while the 
organs available for transplant are 13,522 in 2010 and 1114 in 2011 according to the 
registration database reported by U.S. Department of Health and Human Services (5). 
This also reflects on 40% increase of death on the waiting list for a kidney transplant (3-
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5). Other factors that limit the long-term survival rate of kidney transplant recipients are 
rejection, infection, drug-related toxicities, and many others post-transplant 
complications. 
2. Changes in Kidney Donation and Utilization 
Analyses on kidney transplantation in the U.S. indicate an overall increasing trend 
in transplant candidate selection, preparation, and donor kidney utilization (6). Transplant 
from living kidney donors, either related or unrelated, has been motivated with ethical 
justification of steadily high survival rates among recipients even when compared with 
those from deceased donors with equivalent degrees of human leukocyte antigen (HLA) 
matching (4,6).  
The standards of transplantable organs harvested from deceased donors were also 
modified within the past decades in attempt to expand the kidney pool for transplant (6). 
Previous deceased donor organs which were deemed to be “marginal” due to advanced 
age, a history of hypertension or diabetes mellitus, prolonged cold-ischemia time, or 
elevated serum creatinine concentration at the time of organ harvesting are now 
categorized into a separate kidney transplant waiting list for recipients willing to accept 
organs based on “expanded donor criteria” (6-8).  
II. Immunology in Kidney Transplantation 
1. Immune Response to Kidney Allograft 
As kidney transplantation usually involves placement of kidney allografts of 
immunologically different individuals, transplant recipients‟ immune response is a major 
determinant of overall outcome of the transplant. After allogenic human leukocyte 
antigens are presented for recognition by T cells, either via direct or indirect 
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presentations, recipient T and B cells provoke various effector mechanisms of the defense 
systems to fight against foreign donor antigens (8,9). As this implies, the larger the 
number of HLA alleles that are matched between the donor and recipient, the better the 
graft survival, especially in the first year after transplantation (9).  
2. Pathogenesis of Kidney Transplant Rejection 
 Table 1 below summarizes the experience of rejection based on histopathologic 
patterns in renal allograft. 
Table 1: Classification of Allograft Rejection 
CLASSIFICATION OF REJECTION 
Types  Time Course Pathological Features 
Hyperacute  Minutes to hours Complement activation 
Endothelial damage 
Inflammation thrombosis 
Acute  Weeks to months 
(varied) 
Parenchymal cell damage 
Interstitial inflammation 
Endothelialitis 
Chronic  Months to years Arteriosclerosis 
Intimal smooth muscle 
proliferation 
Vessel occlusion 
 
Hyperacute Rejection. The presence of donor enthothelial antigens within 
minutes to hours after host blood vessels are anastomosed to graft vessels triggers 
antidonor antibodies (8). This activates the complement system resulting in thrombotic 
occlusion of the graft vasculature, which can lead to an irreversible ischemic change in 
the kidney allograft (8). Hyperacute rejection, thus, can cause immediate or near 
immediate loss of graft function (8-10). Patho-morphology of this type of rejection is 
characterized by interstitial hemorrhage, microthrombosis, and inflammation (9). 
Fortunately, in the modern era of transplantation, the risk of hyperacute rejection is 
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preventable with molecular assays such as fluorescence-activated cell sorting cross-detect 
levels of these antibodies (10).  
Acute Rejection. Acute rejection remains a major complication after kidney 
transplantation and a major risk factor for chronic allograft dysfunction (8,9,11). Acute 
rejection mediated by T-lymphocytes is known as acute cellular rejection (ACR) and is 
due to accumulation of mononuclear cells (mostly T cells and macrophages) in the 
interstitium, followed by inflammation of tubules and sometimes of arteries (12). The 
precise mechanisms are yet uncertain but there are two proposed theories on ACR. The 
first theory hypothesizes that cell-mediated cytotoxicity of parenchymal cells is due to the 
participation of CD8
+
 T cells, while the other surmises that local cytokine release is 
mediated by CD4
+
 T cells (8,9). CD8+ class I reactive T cells kill target cells through 
perforin and granzyme B, and through Fas/FasL cytolytic pathways (8,9). Cytokines may 
act directly on tubular cells or indirectly via effects on endothelium and vascular supply. 
The role of regulatory T cells during ACR continues to be characterized (8). 
While activation of antibody-mediated immune response toward HLA class 1 and 
class 2 antigens prior to the transplantation is the underline mechanism of hyperacute 
rejection, arrival of reactive antibodies post-transplantation is the process of acute 
rejection, or to be more specific, antibody-mediated rejection (AMR). The pathologic 
patterns that differentiate this form of acute rejection from hyperacute rejection are 
consequent transmural necrosis of graft vessel wall and acute inflammation (9). Renal 
injuries caused by antibody-mediated rejection can be detected with evidence of focal 
ischemia, severe injury to the endothelial cells of glomeruli and small arterioles in the 
graft, and diffuse intravascular coagulation (9,12).  
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Chronic Rejection. Several episodes of acute rejection and increasing severity of 
rejection lead to development of chronic allograft nephropathy, which is depicted by 
interstitial fibrosis and tubular atrophy (IF/TA) (9,13). IF/TA emphasizes a progressive 
deterioration of renal function, worsening hypertension, proteinurea, and eventually graft 
loss (13,14,15). Although it has been emphasized that immunological and hypertensive 
injuries as well as immunosuppressant-related toxicities contribute to the progression of 
IF/TA, the specific pathogenesis is poorly understood (14,15). A well-documented study 
on histological damages to transplanted kidney shows that early tubulointerstitial damage 
correlates with immunologic factors, including severe acute rejection and persistent 
subclinical rejection in the addition to ischemia–reperfusion injury (16). Later damage of 
chronic allograft nephrotoxicity is characterized by progressive arteriolar hyalinosis, 
ischemic glomerulosclerosis, and further interstitial fibrosis associated with long-term 
calcineurin-inhibitor nephrotoxicity (13-17). 
3. Prevention and Treatment of Allograft Rejection 
The major strategy of kidney transplantation immunology is, therefore, to reduce 
immunogenicity of allograft and to minimize alloantigenic difference between donor and 
recipients. The current standard of practice in preventing acute rejection and graft loss in 
all kidney transplant recipients involves a lifelong immunosuppression therapy. In fact, 
the current standard regimen in most transplant programs in the U.S. consists of induction 
with IL-2R or  lymphocyte-depleting antibody and maintenance with a calcineurin 
inhibitor in combination with mycophenolate mofetil or sirolimus and long-term 
prednisone therapy (18). Calcineurin inhibitors (CNI) that are employed in clinical 
practice in the past 30 years are cyclosporine A (CsA) and Tacrolimus (also known as 
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FK506). The mechanisms and toxicities induced by calcineurin inhibitors in kidney 
allograft of transplant recipients are the focus of this study and will be discussed in great 
details in the following sections of this chapter. 
III. Clinical Diagnosis of Renal Allograft Pathology 
 In addition to traditional clinical parameters such as serum creatinine level, 
estimated glomerular flow rate (GFR), albuminuria and etc., the diagnostic system 
evaluating level of pathophysiological disturbances on the transplanted kidney allograft 
largely relies on biopsy-based histological evidence (19). The current international 
standard classification of renal allograft pathology is the Banff schema. Originated in a 
meeting held in Banff, Canada in 1991, the Banff Working Classification defines 
pathologic criteria of rejection and characterizes renal allograft pathology into five 
categories: 1-antibody-mediated rejection, 2-suspicious of acute rejection, 3-acute 
rejection, 4-chronic sclerosing allograft nephropathy, and 5-other changes not considered 
due to rejection (20). The Banff criteria for rejection are reviewed and updated every two 
years. The latest version was updated in 2007. 
Diagnosis of renal allograft pathology via the Banff criteria in clinical practice, 
however, is complicated by many factors such as subclinical damages, borderline 
changes, tissue fixation, and tissue structural heterogeneity (19, 20). Previous studies on 
the reproducibility of the Banff schema, via kappa statistical tests, which corrects for the 
agreement due by chance, show limited inter- and intra-observer agreement among 
pathological reports for diagnosing and grading of rejection (20). This, however, leaves 
room for molecular biological approaches to introduce the objective techniques of 
microarrays.  
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Microarray technology is based on the principle of complementary, single-
stranded, nucleic acid sequences forming double-stranded, nucleic acid sequences 
forming double-stranded hybrids (22). The high-throughput survey of genes empowered 
by microarray allows many issues such as kidney structural heterogeneity, development, 
and fixation, and certain treatments in the expression of immunoreactive proteins can be 
simultaneously addressed (23). Global gene-to-gene interaction in biological context 
indicated in microarray data can be used to characterize gene expression-regulation in 
post-transplant patients who have received various immunosuppressants (23,24). The 
behavior of genes can be applied as potential markers for monitoring rejection 
susceptibility in biopsy specimens or utilized in monitoring gene expression changes in 
response to therapeutic treatments and guide clinical trials (24). In this context, we have 
implemented the microarray technique to test our hypothesis and quantitatively profile a 
set of genes with differential expression patterns associated with calcineurin inhibitor 
nephrotoxicity.  
IV. Calcineurin Inhibitors as Immunosuppressive Therapeutic Agents 
1. Clinical Administration  
In the early 1980s, cyclosporine A was the first approved calcineurin inhibitor for 
clinical practice. It is a cyclic undecappeptide produced by fungus Hypocladium inflatum 
gams (25). Tacrolimus, a macrolide lactone, extracted from fungus Streptomyces 
tsukubaensis was later discovered and introduced into the class of calcineurin inhibitors 
(26). Since the institution of calcineurin inhibitors, the rate of acute rejection has been 
reduced dramatically reflecting improved short-term survival rates of allograft and kidney 
transplant patients.  
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However, because of their severe side effects, the use of CsA and FK506 has been 
restricted to serious clinical situations such as the prevention of organ transplant rejection 
(25,26). Currently, about 94% of kidney transplant recipients are discharged with a 
calcineurin inhibitor-based immunosuppressive regimen (26). The major toxic effects 
associated with the use of these drugs are nephrotoxicity, hypertension, diabetes, 
neurotoxicity, and gastrointestinal disorders (25-27). Chronic exposure to CNI is also 
believed to contribute to the development of chronic allograft dysfunction –IF/TA, the 
major cause of graft loss in kidney transplantation (27).  
Investigations on crystal structures of cyclosporine and tacrolimus reveal that they 
are unrelated in structures, interact with distinctive cellular receptors, but exert the same 
pharmacological effects on immune system in transplanted allograft (25,28). In vitro 
studies on human cultured CD4 helper T lymphocytes have demonstrated that tacrolimus 
is superior to cyclosporine in selectively inhibiting the secretion of various cytokines, 
including IL-2 (28). Comparative studies on CsA and FK506, furthermore, showed 
different toxicology profiles (27). It was pointed out that tacrolimus is more likely 
associated with diabetes and neurotoxicity but less with hypertension, dyslipidaemia than 
cyclosporine (28). Yet studies on nephrotoxic side effects, or the direct toxicity on kidney 
allograft of transplant patients, indicated that these toxicities are comparable between 
patients treated with tacrolimus and patients treated with cyclosporine (28). 
2. Calcineurin/NFAT Signaling Pathway in T cells 
 Analog studies of cyclosporine and tacrolimus profoundly elucidate their 
immunosuppressive potency via selective inhibition of calcineurin (CN), a cellular 
serine-threonine phosphatase. CN is composed of a catalytic subunit calcineurin A 
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(CNA) and a regulatory subunit calcineurin B (CNB). Molecular analyses of calcineurin 
subunits depict that the N-terminal region of CNA houses its catalytic activity while the 
C-terminal region contains the binding sites for calcineurin B and calmodulin (25,29). 
The binding between the two subunits (A and B) leads to blockade of the CNA active site 
and results in auto-inhibition of calcineurin.  
 Calcineurin‟s activity is tightly regulated by the level of calcium in cells via the 
interaction between binding of calmodulin/calcium and calcineurin regulatory subunit. In 
resting cells, with low intracellular Ca
2+
 level, calcineurin is in inactive form, as CNA 
and CNB remain tightly associated (25,29). In stimulated cells, sustained increase in 
cellular calcium allows the interaction between this ion and calmodulin and triggers a 
conformational change in the regulatory domain of subunit A. It results in the reversibly 
displacement of the auto-inhibitory sequence from the active site and induction of CN‟s 
enzymatic activity (29).  
 Immunological properties of calcineurin primarily rely on its direct role in the 
nuclear factor of activated T-cells (NFAT) signaling pathway, an important signaling 
pathway required for T cell proliferation and activation (Figure 1). NFAT is a family of 
transcription factors, which regulate a diversity of genes in immune cells including 
cytokines, cell-surface receptors, and chemokines (29). Calcineurin binds directly to the 
N-terminal regulatory domain of NFATs, which is extensively phosphorylated in resting 
cells (25,29). Under normal conditions, these phosphorylated residues favor a 
conformational state that results in the masking of the nuclear localization sequences 
(NLS) necessary for NFAT translocation to the nucleus (28,).  Upon an immune 
response, there is a sustained influx of calcium ions into T cell and subsequently activates 
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calcineurin via the mechanism described above. This protein phosphatase removes 
appropriate phosphate groups on NFAT proteins and reveals their signal sequence that 
allows these transcription factors to enter the nucleus and induce transcription of IL-2, 
IL-4, and TNF, which are necessary for T cell to proliferate and be activated (24,28).  
 
Figure 1: Calcineurin/NFAT Signaling Pathway (30) 
 Calcineurin plays a critical role in governing the process of rejection because IL-2, 
in particular, is a powerful inflammatory catalyst implicated in allograft rejection (31). 
The amount of IL-2 produced by the helper T cells significantly influences the extent of 
the immune response (29,31). As described previously, the genes that determine the 
rejection or acceptance of tissue grafts are present in a locus on human leukocyte antigen. 
The central event in the initiation of an immune response is the recognition of the peptide 
in HLA by the T-cell receptor. Cyclosporine and tacrolimus inhibits calcineurin, thus 
preventing T-lymphocyte activity in response to exposure to the peptide from the human 
leukocyte antigens (31). 
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 Recent studies on the function of calcineurin also reveal that this phosphatase has 
other physiological substrates besides NFAT transcription factors. These include 
inhibitor-1, an endogenous inhibitor of protein phosphatase 1 (PP1); DARPP- 32, a 
dopamine- and cAMP-regulated phosphoprotein that also inhibits PP; the microtubule-
associated proteins tau factor, MAP-2, and tubulin; a calmodulin binding protein named 
neuromodulin; the regulatory RII subunit of cAMP dependent protein kinase (PKA); NO 
synthase; the transcription factors MEF2 and Elk-1, components of the synaptic 
endocytic machinery such as dephosphins, the heat shock protein hsp25, and the Bcl2 
family member BAD (25,31). These findings indicate that inhibitory activity of CsA and 
FK506 can cause effects on a variety of canonical pathways, molecular networks, and 
biological functions.  
3. Mechanism of Action of Calcineurin Inhibitors 
 Although calcineurin is distributed through out the body and highly conserved 
among different organisms, T cells are sensitive to calcineurin inhibitors because they 
express a high level of this protein (25,32). Due to their hydrophobic nature, calcineurin 
inhibitors diffuse across the plasma membrane to interact with their cytoplasmic 
receptors. Cyclosporine A binds with high affinity to cyclophilin and tacrolimus binds to 
FK-binding protein 12) (24-30). Cellular receptors of CNI are generally known as 
immunophilins, which are ubiquitously expressed proteins that possess peptidyl-proline 
cis-trans isomerase activity, significant for protein folding and complex stabilization (28, 
30). Via analogs studies, binding of CsA and FK506 to their receptors blocks the prolyl 
isomerase activity of these proteins, but this inhibition is unrelated to the 
immunosuppressive action of these drugs (24). The drug and receptor complexes, 
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however, inhibit calcineurin phosphatase activity by blocking the access of the protein 
substrates to the active site of this enzyme (24).  
 Via the mechanism involving NFAT signaling pathway, reviewed above, the 
blockade of the calcineurin/NFAT pathway appears to be the major mechanism of 
immunosuppression mediated by cyclosporine and tacrolimus. But other transcription 
factors involved in lymphocyte activation such as NFkB and AP1 are partially affected 
by these drugs (24,25,32). However, unlike NFAT, the inhibitory action of CsA and 
FK506 on NFkB and AP1 appears to be indirect. Another alternative mechanism of 
immunosuppression by CNI may involve inhibition of JNK and p38, through a 
calcineurin- independent pathway, but the upstream signaling components targeted by the 
drugs in this inhibitory pathway remain to be unclear (24). 
4. Pharmacokinetics & Pharmacogenetics of Calcineurin Inhibitors  
The pharmacokinetic parameters underline a narrow therapeutic window and a 
large variability in inter-individual response (33). After intestinal absorption, calcineurin 
inhibitor is primarily distributed to erythrocytes and is approximately 99% protein bound 
to both α-acid glycoprotein and albumin (25,34). Cytochrome P450 (CYP) 3A4 and some 
CYP3A5 and P-glycoproteins are important for the process of eliminating of CNI. P-
glycoprotein pumps CNI out of the cell into the intestinal lumen, where metabolism of 
CNI is done by CYP3A4 (34).  
Polymorphism or genetic variations in CYP3A4 and CYP3A5 have been reported 
to affect the pharmacokinetics, specifically, dosing and serum concentrations of 
calcineurin inhibitors in kidney transplant patients (34,35). It has elucidated that 
CYP3A51 carriers have a tacrolimus clearance rate of 25– 45% greater than that of 
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CYP3A53 homozygotes, with proportional dosing needs to maintain adequate 
immunosuppression (35). Since inadequate immunosuppression directly leads to graft 
rejection, understanding the contribution of polymorphisms in pharmacokinetics of CNI 
may be helpful in determining an appropriate starting dosage, rapidly achieving adequate 
immunosuppression, and ultimately improving the outcome of renal transplantation 
(35,36). Clearance range of tacrolimus is from 15 - 70 L per hour (36). For cyclosporine, 
a median apparent clearance is about 29 L per hour with a range from 20 - 50 L per hour 
(36). The dosage can be reduced during maintenance therapy, depending on clinical 
assessments of rejection and tolerability for each patient (36).  
5. Calcineurin Inhibitor Adverse Drug Effects 
The adverse effects associated with calcineurin inhibitor administration adds to 
the range and complexity of the issues surrounding post-transplantation complications in 
transplant recipients as this trades the morbidity and mortality of organ failure for the 
risks of infection, cancer, and toxicities. Three main underline side effects associated 
with calcineurin inhibitors frequently observed in kidney transplant patients are diabetes 
mellitus, hypertension, and nephrotoxicity.  
 Calcineurin Inhibitor-Induced Diabetes Mellitus. It has been demonstrated that 
steroid-based drug regimens increase the risk and actually contribute to hyperglycemia 
and development of post-transplant diabetes mellitus, resemblance to type 2 diabetes 
(37). In the case of calcineurin inhibitor-based therapy, there is a potentially direct impact 
of cyclosporine and tacrolimus on the insulin gene expression at a transcriptional level. 
Studies on calcineurin/NFAT signaling pathway in normal and pathologic -cell function 
show that calcineurin inhibitor, specifically tacrolimus, induce -cell apoptosis and 
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therefore suppress expression of insulin (38).  
 Calcineurin Inhibitor-Induced Hypertension. Since calcineurin inhibitors disturb 
the balance of vasoconstriction and vasodilation affecting homeostasis and blood 
pressure, they cause a decrease in glomerular filtration rate and enhanced sodium 
reabsorption in the renal tubules (39,40). The mechanism involves an increase in intra-
renal renin expression, local endothelin-1, and thromboxane but a reduction in intra-renal 
nitric oxide and prostaglandin (39,40). Alternative mechanisms are via activation of the 
sympathetic nervous system and disturbance of sodium and water retention (41).  
 Calcineurin Inhibitor-induced Nephrotoxicity. Calcineurin inhibitors are thought 
to produce nephrotoxicity, which alters the kidney function and architecture. In 
particular, chronic exposure to CNI induces macrophage infiltration and interstitial 
fibrosis on kidney biopsy (24,34,41). Hypertension and adverse drug effects are tightly 
associated, so the mechanisms involved in cyclosporine- induced hypertension could also 
influence its adverse effects on the kidney (34,41). 
V. Calcineurin Inhibitor Nephrotoxicity 
Nephrotoxicity is observed not only in transplanted kidneys but also in native 
kidneys in patients who receive CNI treatment after other organ transplant or in patients 
suffering from autoimmune diseases (24,34,41). A well-documented research on long-
term assessment of kidney transplant patients treated with cyclosporine (26) reports the 
progression of nephrotoxicity events in 888 biopsies collected from 99 transplant 
recipients. As early as the first year after transplantation, more than 50% of these biopsies 
show signs of toxicities altering kidney‟s architecture and function. After 10 years, 
virtually all biopsies were diagnosed with chronic cyclosporine-induced nephrotoxicity. 
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Previous studies on toxicology profile of CNI indicate that allograft treated with 
tacrolimus and cyclosporine share the same nephrotoxic side effects (41). 
1. Acute Nephrotoxicity 
 Acute nephrotoxicity induced by calcineurin inhibitors is characterized by 
hemodynamic-mediated insults to nephrons of kidney allograft, which are reversible with 
dose reduction or CNI withdrawal. The major signs of acute nephrotoxicity include a 
decrease in glomerular flow rate, acute arteriolopathy, tubular vacuolization, and 
thrombotic microangiopathy (41). At molecular level, calcineurin inhibitors alter kidney 
hemodynamic via disturbance of the balance between vasoconstrictive and vasodilator 
mediators.  
There is an increase in endothelin, a potent vasoconstrictor (41). The mechanism 
underlying CNI-induced increase in endothelin is still uncharacterized, yet, endothelin 
has been found widely released in the kidney and vascular beds of allograft treated with 
calcineurin inhibitors (34,41). Activation of renin-angiotensin system (RAS), 
furthermore, causes arteriolar vasoconstriction by direct effect on juxtaglomerular cells 
and indirect effect on renal vasculature (41). Through the action of angiotensin II, RAS 
activation causes an overall rise in renal vascular resistance. Vasoconstrictory effect of 
angiotensin II, mediated by calcineurin inhibitor administration, is also seen in smooth 
muscle cells by influences on intracellular calcium stores, smooth muscle cell phenotypic 
maintenance, and contractility (25,41).   
As action of calcineurin inhibitors also causes inhibition of NO synthesis, this 
results in endothelium-dependent NO-mediated renal vasodilation (24,41). This is 
believed as the main mechanism of cyclosporine-induced hypertension and decreased 
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GFR (25,41). Formation of free radicals and activation of the sympathetic nerve could 
also contribute to the increase renal vascular resistance and secondarily decreased GFR.  
In tubular cells, nephrotoxicity induces enlargement of the endoplasmic reticulum 
and increased lysosomes, resulting in isometric vacuolization of the tubular cytoplasm, a 
morphologic hallmark of acute calcineurin inhibitor nephrotoxicity (24,25,26,34,41). 
However, vacuolization is also observed in renal ischemia or tubular epithelial injury 
cause by intravenous administration of hyperosmotic fluids but in absence of renal 
dysfunction (41). It is also found in allograft treated with steroid and azathioprine (41). 
Some evidence also indicates formation of inclusion bodies in the tubular cytoplasm, 
which represent giant mitochondria and autolysomes, possibly due to ischemic injury 
(41). Thrombotic microangiopathy marks evidence of acute nephrotoxicity and 
underlying endothelial injury secondary to vasoconstriction-associated ischemia, in 
addition to an increase platelet aggregation and activation of pro-thrombotic factors 
(24,41).  
2. Chronic Nephrotoxicity 
Chronic calcineurin inhibitor nephrotoxicity is characterized by irreversible 
damages to the renal architecture and function. Long-term exposure to cyclosporine and 
tacrolimus show the same spectrum of induced toxicities in the vessels, tubulo-
intertitium, and glomeruli. The hallmark patho-morphologies of chronic calcineurin 
inihibitor nehphrotoxicity include 1-arteriolar hyalinosis, 2-thickening and fibrosis of 
Bowman‟s capsule and focal segmental or global glomerular sclerosis, and 3-tubular 
atrophy and interstitial fibrosis (41). Arteriolar hyalinosis occurs when nodular hyaline 
deposits in the media of afferent arterioles to replace of necrotic smooth muscle cells. 
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Deposition of these focal lumpy proteins at the periphery of the wall of afferent arterioles 
causes narrowing of the vascular lumen.  
Allografts of kidney transplant recipients treated with calcineurin inhibitors also 
show evidence of glomerular injury such as global glomeruloslecorsis and secondary 
gomerular ischemia (41). Global glomerulosclerosis is resulted from sever arteriolar 
hyalinosis and arteriolopathy. Secondary glomerular ischemia obversed in calcineurin 
inhibitor nephrotoxicity has similar profile as that seen in diabetes mellitus (24,34,41).  
Arteriolopathy and narrowing of the arteriolar lumen are believed to be the major 
contributors to the development of calcineurin inhibitor induced interstitial fibrosis and 
tubular atrophy. Local ischemia of the tubulo-interstitial compartment leads to formation 
of free radicals and reactive oxygen species as well as consequences of cellular injury and 
apoptosis (41). The proposed mechanisms indicate directly activation of apoptosis gene 
by calcineurin inhibitors in tubular and interstitial cells (41). These mechanisms are 
hypothesized to underlie the contribution of calcineurin inhibitor nephrotoxicity to the 
development of IF/TA.    
Another major mechanism, which is believed to complicate chronic CNI 
toxicities, is induced epithelial mesenchymal transition (EMT) due to up-regulation of 
TGF (25,41). TGF promotes degradation while reducing production of extracellular 
matrix proteins. EMT is a multistep process in which renal tubular epithelial cells lose 
their cell morphology and acquire new characteristic features of mesenchyme. Loss of 
cell-cell adhesion through down-regulation of E-cadherin destruction of basement 
membrane seen in EMT causes cell migration and invasion.  
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Some of these effects could be independent of calcineurin inhibition, because the 
binding of these drugs to different immunophilins could also interfere with their 
physiological functions (24). In this regard, CsA has been shown to inhibit the opening of 
mitochondrial permeability transition pore, which is involved in cell death, by binding to 
cyclophilin-D and thus removing this immunophilin from the complex pore (42). It is 
possible that CsA/FK506-dependent toxicity may result from interference of the drugs 
with calcineurin substrates or target genes of NFAT in non-immune cells, and there are 
several CN-regulated processes that may be important in this regard (24,41). These kinds 
of interference may underlie the toxic effects of CsA and FK506 on the physiological 
functioning of kidney.  
VI. Challenges In Drug Therapeutic Monitoring And Management 
Both of these immunosuppressive agents have a narrow therapeutic window and 
low correlation between dose-toxicity (35). This explains why plasma level of CNIs fails 
to predict either rejection or toxicity (41).  Clinical differential diagnosis of CNI faces 
further challenges as responses to drug absorption, distribution, metabolism, and 
elimination of CsA and tacrolimus are highly varied not only among individuals but also 
within the body. Pharmacokinetic and pharmacogentic studies of calcineurin inhibitors 
indicate a variability profile with high inter-individual difference. Genetic predisposition 
of cytochromic enzymes CYP3A4 and CYP3A5, which are responsible for metabolism of 
CNIs in the intestine and the liver, implies varying metabolic capacity accompanied with 
sources of dysfunction or failure contributed by induced nephrotoxicity (36). As a result, 
it undermines the effectiveness of the current routine therapeutic monitoring effort and 
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suggests the need of developing an efficient system of clinical assessment of toxicities in 
CNI treated patients. 
Histological findings in acute nephrotoxicity indicate isometric vacuolization of 
the tubular cytoplasm, smooth muscle cell degeneration, and thrombotic microangiopathy 
(24). Yet, these morphological diagnoses have poor reproducibility and many of these 
conditions have been seen as secondary to other toxicity and injury in renal allograft such 
as acute immunology-mediated rejection (41). Due to the direct involvement of T-cell 
signaling pathway in their mechanism of action, CNI shares many common mediators 
with acute cellular rejection (41). Microscopic evidence shows that thrombotic 
microangiopathy due to cyclosporine toxicity, moreover, looks morphologically identical 
to that seen with humoral rejection in kidney transplantation (43).  
For the past 30 years, cyclosporine A and tacrolimus are known as the most 
potent, specific and well-known inhibitors of calcineurin (24). Other classes of 
immunosuppressants used in kidney transplantation beside calcineurin inhibitors are 
corticosteroids, antimetabolites (mycophenolate mofetil, mycophenolate sodium, and 
azathioprine), and target-of-rapamycin-inhibitor (mTOR) (sirolimus and everolimus). 
They have been the targets of many researches in comparison to CNI in term of drug 
efficacy for sufficient immunosuppression and undesirable drug-induced toxicities.  
Despite the apparent affects, they did not protect allograft from insults and injury 
in long-term exposure (44-52). Among them, mTORs show the most severe adverse 
effects, including hypertriglyceridemia, thrombocytopenia, and leucopenia besides 
proteinuria (49). Without long-term validation in sustaining protective immune response 
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and adequate suppression of the residual response to the graft, there is a lack of consistent 
results on literature in regards of finding a substitution for CNI in kidney transplantation. 
In other words, it is essential to detect subclinical renal injuries in CNI treated 
allograft to guide therapeutic maneuvers of immunosuppressive regimens in kidney 
transplantation. Identification of molecular signatures based on analyses of CNI 
nephrotoxicity disease pathways and differential gene expression allow the establishment 
of a standardized and non-invasive system of specific biomarkers characterizing 
pathologies of CNI nephrotoxicity and its potential contribution to the development of 
IF/TA. The outcome will offer the potential of stratifying CNI nephrotoxicity and 
possibly optimizing the benefit to risk ratio of drug treatment by using biomarkers as 
diagnostic tests. 
VII. Study Rationale 
Adverse drug effects induced by calcineurin inhibitors cause nephrotoxicity, 
which leads to allograft dysfunction and possibly to late-term graft loss in kidney 
transplant recipients. A differential diagnosis of this toxicity remains a clinical challenge 
because of the drug‟s low dose-toxicity correlation and varying individual susceptibility. 
We hypothesize that calcineurin inhibitor nephrotoxicity follows specific disease 
pathways and has significant molecular signatures that differentiate it from other 
diagnoses such as interstitial fibrosis/tubular atrophy and acute cellular and humoral 
rejection in kidney transplantation. Moreover, we postulate that CNI-induced toxicity 
profiles contribute to the IF/TA signatures. As calcineurin inhibitors are used not only to 
prevent acute clinical rejection but also to maintain the functionality of the allograft, 
identification of these gene signatures is important in kidney transplant patient 
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management as they can be used to monitor calcineurin inhibitor therapeutic effect and 
toxicity and also to optimize immunosuppression therapy in kidney transplantation.     
VIII. Specific Aims 
The following specific aims will be used to test the overall hypothesis: 
Aim 1 – To identify specific gene expression changes associated with calcineurin 
inhibitor nephrotoxicity when compared with normal function allograft under 
calcineurin inhibitor therapy in kidney transplant recipients. 
Aim 2 – To validate a set of differentially expressed genes from the microarray 
results using real-time PCR. 
Aim 3 – To validate differential expression of the candidate signatures, identified 
in Aim 2, in an independent set of kidney samples.  
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CHAPTER 2: RESEARCH MATERIALS AND METHODS 
 
 
I. Patient and Sample Selection 
 This research project involved 27 kidney-transplant-recipients of deceased donor 
kidneys. Written informed consent was obtained from all patients. All samples were 
collected from biopsies of these patients at 9 month or later post transplantation using an 
18-gauge biopsy needle. All the biopsies were histologically evaluated according to the 
Banff criteria and categorized into appropriate groups. Calcineurin Inhibitor (CNI) group 
included 9 patients with reported biopsy histological changes consistent with CNI 
nephrotoxicity described in the revised Banff „07 schema at least 9 months after 
transplantation. Interstitial fibrosis/tubular atrophy (IF/TA) group was consisted of 10 
patients with reported biopsy histological changes consistent with IF/TA of the Banff 
criteria at 9 months or later after transplantation. Normal function allograft (NFA) group 
was consisted of 8 patients with 9 months or longer follow up with a continuing 
glomerular filtration rate (GFR) of >60ml/min/1.73m
2
 with no reported incidence of CNI 
and/or ACR. The biopsies were instantly submerged in RNAlater (Ambion, Austin, Tx, 
USA) and homogenized. 
II. RNA Isolation from Kidney Tissues 
1. RNA Isolation From Frozen Tissues 
TRIZOL reagent was used to extract total RNA from frozen kidney tissues for our 
microarray analysis because it demonstrated to perform well with small quantities of 
tissues (50-100mg) of human and other species for research purposes according to its 
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manufacturer.  RNA isolation with TRIZOL reagents also allows maintaining the 
integrity of the RNA while disrupting cells and dissolving cell components. RNAs 
yielded are free of protein and DNA contamination, which greatly contribute to the 
quality of RNA to be used in real-time PCR reactions and further analysis.  
The reagent is a mono-phasic solution of phenol and guanidine isothiocyanate. 
During sample homogenization or lysis, TRIZOL reagent maintains the integrity of the 
RNA, while disrupting cells and dissolving cell components. Addition of chloroform 
followed by centrifugation, separates the solution into an aqueous phase and an organic 
phase. RNA remains exclusively in the aqueous phase. After transfer of the aqueous 
phase, the RNA is recovered by precipitation with isopropyl alcohol. After removal of the 
aqueous phase, the DNA and proteins in the sample can be recovered by sequential 
precipitation. Precipitation with ethanol yields DNA from the interphase and an 
additional precipitation with isopropyl alcohol yields proteins from the organic phase.   
2. RNA Isolation from Formalin-Fixed, Paraffin-Embedded Tissues 
 RNA isolation was performed using the High Pure RNA Paraffin Kit, 2009, Roche 
for formalin-fixed, paraffin-embedded (FFPE) samples/tissues in accordance with the 
manufacturer‟s protocol. This kit was chosen for the study because it is specifically 
designed to extract total nucleic acids (RNA, miRNA, and DNA) from FFPE tissues and 
according to its manufacturer, the recovered products are suitable for quantitative real-
time RT-PCR (55).  
 The formalin-fixed and paraffin-embedded kidney sections of 5m thickness were 
incubated at in xylene solution overnight to initiate the de-paraffinization step. Once the 
paraffin melted and separated from the tissue samples, several washes with ethanol were 
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carried out in order to remove the excess xylene from the sample and accelerate drying of 
the tissue. Digestion buffer and protease were then added to the solution and allowed to 
incubate at 55C overnight to break and free the covalent bonds between the proteins and 
the nucleic acids. Then a series of rigorous washing steps was necessary to purify the 
nucleic acids. The final products are captured on the provided glass-fiber filter. The 
isolated RNA was stored immediately at -80C freezer until needed for later analyzing. 
III. Quantity Measurement and Quality Assessment of Isolated RNA 
 To determine quantity and quality of RNA in each sample, spectrophotometer 
readings were analyzed. 1L of RNA isolated from each sample was aliquotted for 
spectrophotometer reading using NanoDrop 1000 Spectrophotometer. The absorbance 
reading at 260 nm was used to calculate the RNA concentration and the ratio of A260/A280 
absorbance readings were used to measure the level of RNA purity from any DNA 
contamination. Typically, the ratio of 1.8-2.1 would be the ideal values for these isolated 
samples. The ratio of A260/A270 absorbance readings was used to observe for any 
contamination with phenol.  
RNA purity as measured by spectrophotometer is deemed sufficient, providing 
the ratios satisfy the criteria A260nm/A280nm >1.8 and A260nm/A270nm >1.3. 
Additionally, the RNA integrity, assessed by capillary electrophoresis using the Agilent 
Bioanalyzer (Agilent Technologies), must meet the criteria that the 28S/18S ratio >1.5. 
We established a cutoff value of 30% rRNA contribution to the total area under the 
electropherogram for RNA samples to be considered as intact or undergraded. Products 
of cDNA synthesis and in vitro transcription (IVT) were tested using the Agilent 2100 
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Bionalyzer (cDNA synthesis 1.5 kb < cDNA < 5.0 kb; IVT 1.0 kb < cRNA < 4.5 kb). 
Assessment of RNA quality was also made using data from the hybridized GeneChips. 
IV. Real Time- QPCR 
 TaqMan Q-PCR (Real Time – Polymerase Chain Reaction) was carried out for 
the amplification step of the PCR products from the cDNA, using the TaqMan Universal 
Master Mix without AmpErase UNG (uracil-N-glycosylase) (Figure 3). The purpose of 
UNG is to prevent PCR carryover products by hydrolyzing any uracil-glycosidic bonds to 
block DNA polymerase replication. However, due to the fact that many of our RNA 
samples being fragmented and degraded from FFPE processing and being aged, it was 
decided to exclude the AmpErase UNG from the Master Mix so we could maximize the 
RNA that remained in our samples. 1.0L of the RT products was added to the 19.0L of 
the reaction mixtures. The ABI Prism 7700 Sequence Detector was set at conditions of 
95C for 10 minutes (denaturation step), 92C for 15 seconds (annealing step), and 60C 
for 60 seconds (extension step), which was repeated for 40 cycles. The amplification for 
mRNA was performed in duplicates along with the endogenous control GAPDH 
(Glyceraldehyde-3-phosphate dehydrogenase). GAPDH was employed as the 
housekeeping gene because it is stably expressed under the defined experimental 
conditions and sufficiently abundant across different tissues and cell types (including 
kidney).  
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   Figure 2: An Overview of Taqman Protocol (Taqman protocol) 
 What makes this assay robust from any other PCR is that TaqMan uses a sequence 
specific probe that anneals to the complementary sequence of the interested target site. 
The probe contains a FAM
tm
 reporter dye at the 5‟ prime end and a nonfluorescent 
quencher (NFQ) at the 3‟ prime end, followed by a minor groove binder (MGB), which 
prevents probe lengthening. When the probe binds to its complementary sequence in 
between the forward and reverse primer sites during PCR, the distance between the 
reporter dye and the quencher dye prevents any florescence activity (Figure 4). However, 
once the DNA polymerase begins synthesizing the new strand and reaches the annealed 
probe, it will cleave the probe, free the reporter dye from the quencher dye, and the 
separation will cause the reporter dye to fluoresce. The ABI Prism 7700 Sequence 
Detector will capture the fluorescence signal, indicating that the target of interest has 
been detected and amplified.  
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   Figure 3: Basics Of 5‟Nuclease Assay (Taqman Protocol) 
 The results portrayed amplification curves and Critical Threshold (Ct) values for 
each reaction. The duplicate Ct values for each sample were averaged. No template 
controls (NTC) were also included in each run to ensure no false positive had occurred. 
The Ct value of the mRNA was subtracted from the Ct value of the GAPDH to give the 
first delta Ct value. Delta-delta calculations were carried out to evaluate the fold change 
between the control group and the group of interest. 
V. Description Of Microarray Assay 
 Study of gene expression in our study was done using Affymetrix microarray 
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technology. According to the manufacturer, up to 1.3 million different oligonucleotide 
probes are synthesized on each Affymetrix array. Each oligonucleotide is located in a 
specific area on the array called a probe cell. Each probe cell contains hundreds of 
thousands to millions of copies of a given oligonucleotide. Probe arrays are manufactured 
in a series of cycles. Initially, a glass substrate is coated with linkers containing 
photolabile protecting groups. Then, a mask is applied that exposes selected portions of 
the probe array to ultraviolet light. 
Illumination removes the photolabile protecting groups enabling selective 
nucleoside phosphoramidite addition only at the previously exposed sites. Next, a 
different mask is applied and the cycle of illumination and chemical coupling is 
performed again. By repeating this cycle, a specific set of oligonucleotide probes is 
synthesized with each probe type in a known location. The completed probe arrays are 
packaged into cartridges. Biotin labeled RNA fragments are hybridized into probe arrays 
and stained with streptavidin phycoerythrin conjugate and scanned by the 
GeneArray® Scanner or the GeneChip® Scanner 3000. The amount of light emitted at 570 
nm is proportional to the bound target at each location on the probe array  
 With minor modifications, the sample preparation protocol followed the Affymetrix 
GeneChip Expression Analysis manual (Santa Clara, CA, USA). Briefly, total RNA was 
reverse-transcribed using T7-polydT primer, and converted into double-stranded cDNA 
using Superscript Choice System (One-Cycle Target Labeling and Control Reagents, 
Affymetrix), with templates used for an in vitro transcription reaction at 37°C for 8 h to 
yield biotin-labeled antisense cRNA. The labeled cRNA was chemically fragmented and 
made into a hybridization cocktail according to the Affymetrix GeneChip protocol, and 
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was then hybridized to U133A 2.0 GeneChip probe arrays (Affymetrix). The array image 
was generated by the high-resolution GeneChip Scanner 3000 (Affymetrix). All CEL 
files all chips passed quality control, the data were processed using Affymetrix GeneChip 
Operating software.  
VI. Microarray Data Analysis 
 Probe set expression summaries for the Affymetrix GeneChip data were calculated 
using the robust multiarray average method. Statistical methods including linear 
regression and empirical Bayes were used to discriminate the gene signals under different 
conditions. P-value was the main criterion to select the differentially expressed genes. A 
genes with p-value less than 0.001 were considered as potentially differentially expressed 
under the pathological conditions (either CNI or IF/TA). Normal function allograft was 
used as the control group. The results were presented in Venn diagram. 
VII. Gene Annotation 
 Gene ontology and gene interaction analyses were executed using Ingenuity 
Pathways Analysis tools 9.0 (http:// www.ingenuity.com). The gene lists containing 
Entrez GeneIDs as clone identifiers, as well as fold-change values from corresponding 
supervised analyses, were mapped to their corresponding gene object in the Ingenuity 
Pathways Knowledge Base (IPKB). These so-called focus genes were then used in the 
network generation algorithm, based on the curated list of molecular interactions in 
IPKB. Significance for the enrichment of the genes in a network with particular biologic 
functions was determined by the right-tailed Fisher exact test, using a list of all the genes 
on the array as a reference set. In addition, an HTML page listing all significant probe 
sets with their associated Entrez ID, gene symbol, Unigene ID, chromosomal location, 
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and gene name with appropriate hyper links were produced to expedite follow-up. 
VIII. Validation of Microarray Data 
1. Selection of Kidney Biopsies 
To validate our microarray results, we carried out a quantitative real time PCR for 
genes selected as the potential signatures characterizing calcineurin inhibitor 
nephrotoxicity and its speculated progression to the development of IF/TA. RNA samples 
used to validate were isolated from kidney biopsies that were used in microarray analysis  
CNI group included 11 samples with reported histological changes consistent with 
CNI nephrotoxicity at least 9 months after transplantation. Interstitial fibrosis/tubular 
atrophy (IF/TA) group was consisted of 7 samples with reported biopsy histological 
changes consistent with IF/TA of the Banff criteria at 9 months or later after 
transplantation. Normal allograft (NA) group was consisted of 9 samples with 9 months 
or longer follow up with a continuing estimated glomerular filtration rate (GFR) of 
>60ml/min/1.73m
2
 with no reported incidence of CNI and/or ACR. 
2. Q-PCR Validation of Microarray Analysis 
Each assay consisted of two unlabeled PCR primers and a FAM dye-labeled 
TaqMan MGB probe. The endogenous control, GAPDH, was detected with a VIC dye-
labeled TaqMan MGB probe (human GAPDH endogenous control, VIC/ TAMRA Probe; 
Primer Limited, Applied Biosystems). Total RNA from each sample was subjected to 
reverse transcription using TaqMan Reverse Transcription Reagents (Applied 
Biosystems) according to the manufacturer‟s protocol. Real-time PCR reactions were 
carried out in a 20-μL reaction mixture using an ABI Prism 7700 sequence detection 
system (Applied Biosystems).  
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All amplifications were carried out in duplicate, and threshold cycle scores were 
averaged for calculations of relative expression values. The Ct scores for genes of interest 
were normalized against Ct scores for the corresponding GAPDH control. Relative 
expression was determined by the following calculation where the amount of target is 
normalized to an endogenous reference (GAPDH RNA) and relative to an arbitrary 
calibrator (the reference class of patients used in the comparison) (18): relative 
expression = 2
-ΔΔCt
, where ΔΔCt = ΔCt experimental group – ΔCt calibrator group. 
3. Statistical Analysis 
Student t-tests were used to compare the expression of RGS1, CXCR4, and TGIF1 in 
samples (CNI, IF/TA, and NA groups) using their Ct values  (Ct =Ct (target gene) – Ct 
(endogenous control)). Pearson‟s Correlation Analysis (using delta Ct values) was used to 
observe the correlation between (1) the expression of target genes (RGS1, CXCR4, and 
TGIF1) and the pathology of CNI nephrotoxicity and (2) the expression of target genes 
(RGS1, CXCR4, and TGIF1) and the pathology of IF/TA. Pearson‟s Correlation 
Coefficient of 1 indicates strong correlation. For all of the above tests, p<0.05 was 
considered significant.  
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CHAPTER 3: RESULTS 
 
 
I. Patient Demographics and Clinical Values 
Molecular biological analysis was done based on biopsies of 27 kidney-
transplant-recipients of deceased donors (23 patients are treated with tacrolimus and 4 
patients are treated with cyclosporine). Table 2 bellow summarizes patient demographic 
information of this study and clinical data.  
Table 2: Patient Sample Demographics And Available Clinical Values  
NFA: Normal Function Allograft, CNI: Calcineurin Inhibitor; IF/TA: Interstitial Fibrosis/Tubular Atrophy; SD: 
Standard Deviation; Bx: Biopsy, eGFR: estimated Glomerular Filtration Rate. 
 
 
NFA (N=8) 
Average SD 
CNI (N=9) 
Average SD 
IF/TA (N=10) 
Average SD 
Recipient age (years) 
 
49.0 + 14.7 50.9 + 10.4 46.4 + 9.6 
Recipient race 
White 
African American 
Others 
 
1 
6 
1 
 
2 
7 
0 
 
 
1 
9 
0 
Donor age (years) 36.0 + 14.4 54.8 + 4.4 37.7 + 11.3 
Donor race 
White 
African American 
Others 
 
4 
4 
0 
 
 
5 
3 
1 
 
 
6 
4 
0 
Creatinine (mg/dL) 
Day 1 
Day 2 
1 week 
1 month 
3 months 
9 months 
12 months 
At time of Bx 
 
 
6.8 + 1.8 
5.2 + 1.5 
1.7 + 1.1 
1.2 + 0.3 
1.2 + 0.5 
1.0 + 1.6 
1.3 + 0.6 
1.24 + 0.6 
 
7.3 + 2.3 
6.5 + 1.9 
4.5 + 1.7 
2.6 + 2.2 
2.3 + 1.0 
3.0 + 1.4 
2.3 + 0.8 
3.17 + 2.0 
 
8.8 + 2.6 
8.1 + 2.6 
6.0 + 1.8 
1.7 + 0.8 
1.5 + 0.3 
2.0 + 0.8 
1.9 + 1.0 
6.44 + 1.6 
eGFR at 12 months > 60 
 
33 + 12.9 <25 
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 As described in chapter 2, Research Materials and Method, the kidney biopsies 
used for our study were categorized into three groups, including normal function allograft 
(NFA), calcineurin inhibitor nephrotoxicity (CNI), and interstitial fibrosis/tubular atrophy 
(IF/TA) according to the Banff ‟07 for Renal Allograft Pathology (Table 3).  
Table 3: Histological Evaluation of Kidney Biopsies Using Banff ‟07 Update. 
Patients Banff ’07 Classification for 
Renal Allograft Pathology 
Diagnosis 
1 Banff 5I Normal Function Allograft 
2 Banff 5I Normal Function Allograft 
3 Banff 5I Normal Function Allograft 
4 Banff 5I Normal Function Allograft 
5 Banff 5I Normal Function Allograft 
6 Banff 5I Normal Function Allograft 
7 Banff 5I Normal Function Allograft 
8 Banff 5I  Normal Function Allograft 
9 Banff 6 Calcineurin-Inhibitor Nephrotoxicity 
10 Banff 6 Calcineurin-Inhibitor Nephrotoxicity 
11 Banff 6 Calcineurin-Inhibitor Nephrotoxicity 
12 Banff 6 Calcineurin-Inhibitor Nephrotoxicity 
13 Banff 6 Calcineurin-Inhibitor Nephrotoxicity 
14 Banff 6 Calcineurin-Inhibitor Nephrotoxicity 
15 Banff 6 Calcineurin-Inhibitor Nephrotoxicity 
16 Banff 6 Calcineurin-Inhibitor Nephrotoxicity 
17 Banff 6 Calcineurin-Inhibitor Nephrotoxicity 
18 Banff 5II Interstitial Fibrosis/Tubular Atrophy 
19 Banff 5II Interstitial Fibrosis/Tubular Atrophy 
20 Banff 5III Interstitial Fibrosis/Tubular Atrophy 
21 Banff 5III Interstitial Fibrosis/Tubular Atrophy 
22 Banff 5II Interstitial Fibrosis/Tubular Atrophy 
23 Banff 5II Interstitial Fibrosis/Tubular Atrophy 
24 Banff 5III Interstitial Fibrosis/Tubular Atrophy 
25 Banff 5III Interstitial Fibrosis/Tubular Atrophy 
26 Banff 5II Interstitial Fibrosis/Tubular Atrophy 
27 Banff 5II Interstitial Fibrosis/Tubular Atrophy 
 
 
II. Microarray Results 
Statistical analysis of microarray data from the biopsies collected at least 9-month 
post-transplantation (based on p-value of less than 0.001) showed that 498 genes were 
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identified as unique differentially expressed genes to the conditions of CNI vs. NFA and 
3371 were unique for IF/TA vs. NFA (Figure 4). The overlapped genes, 449 genes, which 
showed the same direction of gene expression (either up-regulation or down-regulation), 
can possibly contribute to the progression of CNI to IF/TA as seen in figure 9. 
 
Figure 4: Venn Diagram (identified segregation of deregulated  
genes in CNI vs. NFA and IFTA vs. NFA (Using TOPPGENE software) 
 
III. Biological Networks and Pathway Analysis in CNI Population 
 Core analysis was performed to interpret the data set in the context of biological 
processes, pathways and molecular networks.  
1. Top Ten Networks of Interaction  
Probe sets differentially expressed in CNI samples (N = 498) were overlaid onto a 
global molecular network developed from information contained in the IPKB. This is a 
network of gene interactions, which are algorithmically generated and then ranked based 
on a number of score corresponding to the likelihood of a set of genes being found in the 
networks due to chance. To illustrate, a score of 3 indicates that there is a 1/1000 chance 
that focus genes are in a network due to the chance. Therefore, a score of 3 or higher has 
a 99.9% confidence of not being generated by chance alone. Top ten score-based 
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biological networks associated with calcineurin inhibitor nephrotoxicity were reported in 
the Table 4 below.  
Table 4: Biological Networks Ranked By Score in CNI Tissues 
I
D Molecules in Network 
Scor
e 
Focus 
Molecule
s Top Functions 
 1 
 AFF2, AKAP2/PALM2-AKAP2, 
BRD4, DLX4, FH, GRB2, HIBCH, 
Histone h4, HNRNPH1, HNRNPR, 
Importin alpha, Importin beta, KCNB2, 
KPNA3, NUTF2, P-TEFb, PDIA4, 
PHACTR2, PXDN, RBM25, RPL12, 
SAE1, SIRT3, SIRT4, SMARCD3, 
SPEN, SRP19, SYNCRIP, SYT2, 
TBL1X, TNPO1, UBA52, WDR44, 
XPO7, ZBTB7A  42  31 
Post-Translational 
Modification, 
Genetic Disorder, 
Metabolic Disease 
 2 
 ALB, ARF4, CAPG, CD3, CDC42, 
CLCN4, DEFA5, DMWD, Gsk3, 
HAND1, JUN, KIAA0930, KLC1, 
LSR, MAPK8, MBP, MZF1, 
NDUFA5, NRP1, P38 MAPK, 
PLXNA1, PRB3, PRKCA, Pro-
inflammatory Cytokine, SETX, 
SH3BP5, SLC1A1, SPAG9, SUCLG2, 
SYNE1, TCF20, TCR, TRD@, Vegf, 
YWHAB  36  29 
Cellular 
Development, 
Nervous System 
Development and 
Function, Cellular 
Assembly and 
Organization 
 3 
 AAK1, ABCC1, Adaptor protein 2, 
ALDH6A1, ALDOA, AP-3, Ap2 alpha, 
AP2B1, AP3D1, ATPase, BAZ1A, 
C10orf10, CD1B, Clathrin, DLGAP2, 
EHMT2, GABAR-A, GABRA1, 
GABRA5, GABRR2, GRIN2A, 
H3F3A/H3F3B, IL1RAPL1, NECAP2, 
Pias, PLSCR1, QKI, RALBP1, 
RBFOX2, RERE, SHC1, SMARCA5, 
SMCP, SRRM2, Top2  33  27 
Molecular 
Transport, Genetic 
Disorder, 
Neurological 
Disease 
 4 
 APBA1, APBB2, APH1A, APP, 
ATP5J2, BAX, BCL6, CAMKK2, 
CLOCK, COX10, Cytochrome c 
oxidase, DAD1, Dynein, FAM173A, 
FEZ2, Gm-csf, H2AFX, HADH, 
HAP1, IL12 (family), LIN7B, MCL1, 
Notch, PCM1, PSEN2, PYCARD, 
RER1, RTN2, Secretase gamma,  32  28 
Cell Death, Renal 
Necrosis/Cell 
Death, Cellular 
Assembly and 
Organization 
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SGPL1, SMC3, SRI, TIP60, UBXN4, 
ZNF24 
 5 
 26s Proteasome, ALDH1A3, ANP32B, 
ATG12, ATRX, AZGP1, BRD2, 
CCND1, CNOT1, CSN2, Ctbp, 
GATAD2A, Hat, HIST1H4C (includes 
others), HISTONE, Histone h3, 
HNRNPA0, JUNB, KCNA5, KHK, 
MAFF, MBD1, N4BP1, PDE4DIP, 
POP7, PRNP, Ptk, RPL36, Rsk, 
SERBP1, SET, STAT, TGIF1, TP63, 
USP22  32  27 
Cell Cycle, DNA 
Replication, 
Recombination, 
and Repair, Gene 
Expression 
 6 
 ADAM17, AFF1, ARHGEF40, C3, 
CCBP2, CDKN1A, CHEMOKINE, 
Ck2, CTSZ, DNA-directed RNA 
polymerase, DSE, DUSP1, Dynamin, 
GPSM2, GTF2H4, GYPA, Holo RNA 
polymerase II, HRAS, IgG, 
Immunoglobulin, KLF7, MED28, 
MED13L, Mediator, MEF2C, NKTR, 
POLR2D, POLR2L, POLR3C, RNA 
polymerase II, RNF7, STC2, TXLNA, 
VGLL4, ZMPSTE24  30  26 
Organismal Injury 
and 
Abnormalities, 
Cell Cycle, 
Cellular 
Development 
 7 
 APPBP2, C5orf13, CUL2, CYR61, 
DBI, DDX24, EIF5B, FXR2, 
HEATR6, HIF1A, Ikb, LYN, 
MFHAS1, MTDH, MYC, NFkB 
(complex), NFkB (family), NR3C1, 
Orm, OTUB1, PLAGL1, PRRC2C, 
RALYL, RELT, SERINC3, TFAM, 
Tgf beta, TPP2, TSPO, UBE2I, 
UBE2K, Ubiquitin, VDAC3, VIM, 
VOPP1  30  28 
Cell Morphology, 
Hair and Skin 
Development and 
Function, Cell 
Cycle 
 8 
 ADRA1A, AGTR2, Beta Arrestin, 
CYSLTR2, DRD5, F2RL1, FZD2, 
GAB1, GABBR2, GLP1R, GNRHR, 
Gpcr, GPR12, GPR89A/GPR89B, Gs-
coupled receptor, Gαq, HRH4, HTR6, 
HTR1F, HTR3A, HTR3B, MAS1, 
Metalloprotease, P2RY11 (includes 
others), Pik3r, RGS1, RRH, Serotonin 
Receptor, Shc, SRC, TAAR3, TACR2, 
Trk Receptor, VIPR2, VN1R1  30  25 
Hematological 
Disease, 
Immunological 
Disease, 
Inflammatory 
Disease 
 9 
 3‟,5‟-cyclic-nucleotide 
phosphodiesterase, AKAP6, Alpha 
tubulin, ANXA2, APC, APEX1,  29  26 
Protein Synthesis, 
Cell Morphology, 
Gene Expression 
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CLIC4, CYLD, EIF3A, EIF4A1, Eif4g, 
EIF4G3, Hdac, INTS6, MYCN, NRL, 
PABPC4, Pde, PDE10A, PDE4A, 
PDE6A, Pka, Pka catalytic subunit, 
PKP1, RBBP5, Rnr, RPL28, RPL35, 
RPLP0, S100A10, STAU1, STMN1, 
TUBA1A, TUBA1B, VARS 
 
10 
 ACTN1, alcohol group acceptor 
phosphotransferase, ATP2A2, Calpain, 
CBFB, CCND2, CEP170, COIL, 
CSDA, CSNK1A1, Cyclin A, Cyclin 
D, DST, DYRK1A, E2f, EPM2A, 
FJX1, FSH, GSK3B, hCG, HIF3A, 
HIST1H2AB/HIST1H2AE, IGSF1, 
INHBB, INHBC, inhibin, Lh, 
NOTCH2, PAK2, PGK1, RAB14, 
RAB31, Rb, SMYD2, UPP1  29  25 
Gene Expression, 
Organ 
Development, 
Organ 
Morphology 
  
2. Network Exploration 
According to the top ten biological networks significant in CNI population (N = 
498) listed above, network 4 (Figure 5) includes deregulated genes that are involved in 
cell death, renal necrosis/cell death, cellular assembly and organization. The interactions 
of molecules in this network are further explored using IPA tool (www.ingenuity.com) 
and it shows that molecules of multiple mediators including cytochrome c are down-
regulated, while a number of transcription factors are up-regulated. 
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QuickTime™ and a
 decompressor
are needed to see this picture.
 
Figure 5: Interaction Network 4 in CNI vs. NFA.  
The meaning of the node shapes and interaction edges is indicated on legend list on the right.  
 
Another network that is significant to the toxicology profile of calcineurin 
inhibitors is network 8 (Figure 6), with molecules significant in hematological disease, 
immunological disease, and inflammatory disease. It shows a general down regulation 
various the G-protein coupled proteins, which leads to a noticeable up regulation of 
RGS1, regulator of G-protein signaling 1, a molecule that involved in immune response 
and negative regulation of signal transduction. 
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QuickTime™ and a
 decompressor
are needed to see this picture.
 
Figure 6: Interaction Network 8 in CNI vs. NFA.  
The meaning of the node shapes and interaction edges is also indicated on the right.  
 
3. Canonical Pathway Analysis 
Canonical pathway analysis (Figure 7) shows that top pathways that are affected are 
involved in oxidative stress response and also various cell death-signaling pathways (14-
3-3 mediated signaling pathway, p53 signaling pathway, and TGF- signaling pathway 
(Figure 8) in additional to prolactin signaling, rac signaling, cancer, and some others.  
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Figure 7: Top Canonical Pathways in CNI vs. NFA. Each bar represents the percentage of up-
regulated (red) or down-regulated (green) or unaffected/undetected (white) genes within the identified 
pathway. The line represents –log(P value).  
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Figure 8: TGF- Signaling Pathway. Up-regulated genes are shown in red while down-regulated 
genes are shown in green. Unaffected/undetected genes within the identified pathway are in white.  
  
IV. Biological Function and Toxicology Profile of CNI vs. NA and IF/TA vs. NA 
differentially expressed genes 
 Core analysis was also performed to interpret the data set in the context of 
biological function and toxicology profiles between CNI group and IF/TA groups 
1. Pair-wise Comparison Analysis Between CNI and ITA 
In the overlapped genes between CNI and IF/TA (N= 449) as expected, scar 
tissues and irreversible damages characterized ITA indicating the increasing effect of 
these conditions in cell death. However, oxidative stress response played a bigger role in 
calcineurin inhibitor nephrotoxicity than in IF/TA. Some important pathways that 
involved in cellular response to injury and inflammation such as p53 and TGF- 
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signaling pathways were more affected in calcineurin inhibitor nephrotoxicity when 
compared to IF/TA. Yet renal necrosis/cell death is seen much higher allograft diagnosed 
with IF/TA than with calcineurin inhibitor nephrotoxicity. Figure 9 summarizes the 
findings above. 
 
Figure 9: Comparison in Biological Function of CNI vs. IF/TA  
 
2. Functional analysis of the differential gene expression between groups  
In agreement to the above findings, pathology of IFTA underlines a higher degree 
of renal necrosis and cell death as compared to that in calcineurin inhibitor 
nephrotoxicity. However, other injuries to specific compartments of kidney show the 
contrary. Calcineurin inhibitor nephrotoxicity causes more kidney failure, renal nephritis, 
glomerular injury, and also nephrosis. Figure 10 summarizes findings above. 
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Figure 10: Comparison in Toxicology Function of CNI vs. IF/TA 
 
V. Differential Gene Expression Profiling 
 
1. Criteria for Selecting Genes for Validation 
A list of potential gene signatures was selected from the genes annotated for CNI 
vs. NA (N= 498). This list was filtered based on biological significance relevant to 
pathology of CNI nephrotoxicity with support from literature review and IPA reports. To 
determine whether the selected genes were unique to the conditions of CNI 
nephrotoxicity or possibly candidates of CNI contribution to IF/TA, the criteria listed in 
table 4 of each molecule were thoroughly considered.  
Table 5: Criteria For Selecting Genes For Validation 
Criteria For Selecting Genes For Validation: 
1. Significance of probe set‟s p-value < 0.001 
2. Fold changes based on mean expression compared to 
Normal Allograft 2.0 or -2.0 
3. Biological processes/Molecular functions/Canonical 
pathways relevant to CNI nephrotoxiticy  
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3. Candidate Differentially Expressed Genes  
Among several characteristic genes showed differentially expression between CNI 
nephrotoxicity and normal allograft under CNI therapy (N = 498), 9 gene candidates were 
selected (Table 6). In addition to the above criteria, these genes don‟t have significant 
fold changes in IF/TA (due to either not detected or fold change out of the range of 
interest). These genes were also regulated differently via comparison of fold change of 
the same genes in IF/TA vs. NA in the opposite direction (i.e. gene was up regulated in 
CNI but down regulated in IF/TA).  
Table 6: Candidate Genes With Significant Expression in CNI Population. 
DIFFERENTIALLY EXPRESSED GENES IN CNI vs. NFA 
Affy ID Gene Symbol p-Value Fold change based on 
mean expression 
 
216834_at RGS1 
 
9.87E-04 5.305 
203313_s_at 
 
TGIF1 
 
1.22E-04 
 
2.132 
 
200644_at 
 
MARCKSL1 5.36E-04 
 
2.146 
211348_s_at 
 
CDC14B 2.27E-05 
 
2.087 
202376_at 
 
SERPINA3 
 
7.78E-04 
 
 
3.804 
202598_at 
 
S100A13 4.74E-04 
 
2.406 
208993_s_at 
 
PPIG 
 
1.78E-07 
 
3.099 
204863_s_at IL6ST 2.81E-04 
 
2.689 
210305_at PDEDIP 2.25E-04 3.004 
 
Furthermore, out of the differentially expressed genes identified that showed same 
direction of regulation in both CNI nephrotoxicity and IF/TA diagnosed allografts (N = 
449 overlapped genes), 10 gene candidates were selected (Table 7). Besides the criteria 
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above, these genes also characterize both CNI and IFTA with fold changes in the same 
direction (i.e. a gene that is up regulated or down regulated in both conditions). Also 
these fold changes must show significant difference when compared to one another (i.e. 
the difference in fold changes must be greater than 2 times). These candidate genes can 
serve as molecular signatures for further studied in understanding of the contribution of 
CNI nephrotoxicity to the development of IF/TA. 
Table 7: Candidate Genes With Significant Expression In CNI And IF/TA  
(Normal Function Allograft was used as the control group. Several fold change were reported in 
accordance to more than one probe set was detected for the specific genes.) 
DIFFERENTIALLY EXPRESSED GENES IN CNI vs. NFA AND IF/TA vs. NFA 
Affy ID Gene 
Symbol 
p-Value 
CNI vs. NFA 
p-Value  
IF/TA vs. NFA 
Fold change based on 
mean expression 
   CNI vs. 
NFA 
IFTA vs. 
NFA 
209201_x_at 
 
CXCR4 
 
2.26E-04 
 
4.17E-13 3.328 21.573 
 
209880_s_at 
 
PLG 2.10E-04 
 
6.27E-11 -5.335 -39.038 
209309_at 
 
AZGP1 1.58E-12 
 
6.67E-08 -3.295 -53.489 
-8.568 
201041_s_at 
 
DUSP1 6.60E-11 
 
6.94E-06 3.777 11.464 
206332_s_at 
 
IFI16 2.21E-10 
 
2.97E-12 2.716 7.260 
4.255 
3.937 
212587_s_at 
 
PTPRC 2.46E-12 
 
6.75E-07 2.632 14.551 
5.807 
6.177 
-1.453 
221666_s_at 
 
PYCARD 2.16E-08 
 
2.16E-08 2.505 5.973 
219803_at 
 
ANGPTL3 4.33E-14 
 
4.33E-14 -2.805 -35.496 
204704_s_at 
 
ALDOB 1.22E-11 
 
1.22E-11 -2.109 -234.364 
-147.464 
-142.546 
-3.026 
221731_x_at 
 
VCAN 5.86E-13 
 
7.84E-10 4.201 14.006 
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4. Selected Genes for Validation 
With the listed criteria, three genes were chosen for the study (Table 8). These 
genes were further validated using real-time PCR on an independent set of kidney tissues.  
Table 8: Characteristic Genes For CNI Nephrotoxicity 
  Affy ID 
Gene 
Symbol 
Biological Significance To  
CNI Nephrotoxicty 
Reference
s 
1 216834_at RGS1 
Involved in immune response and negative 
regulation of signal transduction 
Over-expressed in regulatory T cells in 
immunology tolerance 54-57 
2 1566901_at TGIF1 
Is an active transcriptional co-repressor of 
SMAD2 in TGF- signaling pathway – 
might involved in the mechanisms of renal 
interstitial fibrosis 58-61 
3 209201_x_at CXCR4 
Interacts with cyclophilin A involved in 
physiological and pathological conditions 
such as human immunodeficiency virus 
infection and cancer metastasis 
Involved in p38-dependent T cell apoptosis 62&63 
 
VI. Q-PCR Confirmation of Microarray Data 
For the selected genes we observed good correlation between QPCR and 
microarray results using 6 CNI samples and 6 NA samples of RNAs that were also used 
in the microarray analysis. The results of two-sample t-tests for this set was calculated 
and reported in table 9. 
                               Table 9: T-test Of Genes Used In Confirmation 
T-tests (* denotes a significant t-test result) 
 RGS1 CXCR4 TGIF1 
CNI vs. NA 0.038* 0.246 0.245 
IF/TA vs. NA 0.006* 0.036* 0.328 
CNI vs. IF/TA 0.412 0.147 0.172 
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The 2-Ct calculations were carried out to demonstrate the relative fold changes 
of RGS1, CXCR4 and TGIF1 in confirmation of the microarray data. The results of these 
calculations were reported in table 10 along with standard deviation for each fold change 
Table 10: Relative Fold Change of Gene Expression 
(With NFA group as reference) 
Relative Fold Change of Target Gene Expression 
Fold 
Change 
 RGS1 CXCR4 TGIF1 
CNI 38.88 + 0.99 3.30 + 1.58 0.32 + 2.73 
IFTA 76.07 + 2.66 9.17 + 1.45 0.89 + 3.70 
  
 To observe the correlation between the level of expression of RGS1, CXCR4, and 
TGIF1 and the pathology of CNI nephrotoxicity as well as the pathology of IF/TA, a 
Pearson‟s Correlation Analysis was calculated. The results were summarized in table 11 
below.   
Table 11: Pearson‟s Correlation Coefficient Values 
Pearson’s Correlation (*denotes a significant correlation) 
 RGS1 CXCR4 TGIF1 
CNI  0.37 -0.65* 0.61* 
IF/TA -0.75* 0.62* 0.21 
 
VII. Q-PCR Validation  
To validate microarray data of RGS1, CXCR4, and TGIF1, real-time PCR was 
performed in an independent set of sample tissues (N= 18, CNI = 11 and NA =7). The 
results of two-sample t-tests, which revealed the significant differential expression of the 
genes of interest between CNI and IF/TA tissues and normal allograft, and between CNI 
and IF/TA groups, were calculated and reported in table 12 below.  
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Table 12: T-test of Genes In Validation 
T-tests (* denotes a significant t-test result) 
 RGS1 CXCR4 TGIF1 
CNI vs. NA 0.015* 0.115 0.755 
IF/TA vs. NA 0.001* 0.004* 0.849 
CNI vs. IF/TA 0.139 0.062 0.836 
 
The 2-Ct calculations were carried out to demonstrate the relative fold changes 
of RGS1, CXCR4 and TGIF1 in study samples of CNI and IFTA (Table 13).  
Table 13: Relative Fold Change of Validated Genes 
(With NFA group as reference) 
Relative Fold Change of Target Gene Expression 
Fold 
Change 
 RGS1 CXCR4 TGIF1 
CNI 15.48 + 0.81 3.09 + 1.09 1.27 + 1.24 
IFTA 42.05 + 2.73 7.96 + 2.67 1.12+ 2.78 
 
Figure 11 summarizes the fold changes based on calculations above of RGS1, 
CXCR4, and TGIF1 in kidney samples of the study. It showed that expression of genes of 
the study had a positive direction in both CNI and IF/TA tissues.  
 
Figure 11: Fold Change In Gene Expression of CXCR4, RGS1 and TGIF1  
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1. RGS1 expression 
The differential expression of mRNA RGS1 in CNI tissues was first evaluated 
through analysis of comparison the gene expression in the CNI tissues versus normal 
allograft, IF/TA tissues versus normal allograft, and between pathological groups  (CNI 
versus IF/TA). Three two-sample t-tests were performed. The t-test values of p = 0.015 
and p = 0.001 showed significant differential expression between pathological groups 
when compared with normal allograft, CNI vs. NA and IF/TA vs. NA respectively. Even 
though the t-test (p = 0.139), performed on the mean Ct values between CNI and IF/TA 
samples, showed no statistical significant differences in the level of RGS1 expression, we 
noticed a positive and up-regulated pattern of this gene expression in IF/TA tissues when 
compared to that in CNI tissues. According to the calculated fold change of RGS1, this 
particular gene expression in IF/TA kidney tissues was about 3 times higher of that in 
CNI kidney samples. Pearson‟s correlation showed a negative correlation of RGS1 in 
IF/TA but not in CNI (-0.75 and 0.37 respectively) or a negative relationship between the 
expression of this gene seen in microarray data and that in q-PCR validation (Aim 2).  
2. TGIF1 Expression 
Since TGIF1 was also collected as one of the three candidate genes for this 
present study on calcineurin inhibitor nephrotoxicity based on its significant in statistical 
microarray value and biological relevance, we also performed real-time PCR reactions 
for this gene to observe and validate the correlation of the gene expression pattern with 
the drug-induced toxicities. Two-sample t-test based on mean Ct values between groups 
of the study did not show any significance in the level of TGIF1 expression in either 
tissues with pathologies (CNI or IF/TA) or tissues of normal allograft. Computation of 
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the gene fold changes in CNI group and IF/TA group showing a large standard deviation 
also confirmed no significant expression level between analysis groups. Despite this, 
expression level of TGIF1 showed a positive correlation (0.61) between microarray data 
analysis and q-PCR validation result in CNI group, according to its Pearson‟s correlation 
coefficient.  
3. CXCR4 Expression 
In a similar with the above assessment of the qPCR results of RGS1 and TGIF1, 
mRNA expression, gene expression patterns of CXCR4 were also mathematically 
evaluated in three pairs of comparison between groups of sample tissues. Student‟s t-test 
with p values of 0.115 and 0.062 suggested no significant differential expression of this 
gene in CNI tissues when compared with normal allograft and also between CNI tissues 
and IF/TA tissues. However, student‟s t-test revealed p = 0.004 indicating differential 
expression of the mean Ct values between IF/TA group and normal allograft being 
statistically significant. Relative fold change of CXCR4 in IF/TA group was calculated to 
be 7.96 and 3.09 in CNI group. According to Pearson‟s Correlation Analysis, CXCR4 
showed significant correlation in both CNI and IF/TA with r=-0.65 and 0.62 respectively.   
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CHAPTER 4: DISCUSSION 
 
 
Cyclosporine and tacrolimus are potent immunosuppressive therapeutic agents, 
which selectively target calcineurin and NFAT signaling pathway to suppress T-
lymphocyte activation and proliferation. Their pharmaceutical benefit in kidney 
transplantation is, however, limited because of undesirable adverse effects. Direct 
toxicities induced by calcineurin inhibitors on kidney allograft, in fact, cause 
nephrotoxicity, which is a complex consequence of disturbance in hemodynamic balance, 
inflammatory response, and structural damages to the nephrons. Retrospective studies on 
calcineurin inhibitors report that, at five years after transplantation, developing 
nephrotoxicity is almost universal in kidney transplant patients (26). 
Reduction in CNI dose, withdrawal of CNI, or CNI-free therapies show 
improvement in signs and symptoms of nephrotoxicity. However, due to high risk of 
acute rejection and lack of long-term validation, calcineurin inhibitors are still widely 
administered as the standard maintenance immunosuppressive therapy in solid-organ 
transplantation (34). Management and treatment of toxicities induced by CsA and FK506 
continue to be a major clinical challenge due to variable individual susceptibilities and 
difficulty in establishing a differential diagnosis.  
We were aware of the impact of gene polymorphism in pharmacokinetics and 
pharmacogenetics on individual response to CNI-induced toxicities on kidney allograft. 
Previous research groups found many genes involved in the renin-angiotensin system, 
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which contributes largely to the disturbance in hemodynamic balance of the transplanted 
kidney, and several others involved in the CNI pharmacokinetics greatly affecting the 
drug efficacy and extend of toxicity in individual body system (26,34,35). Clinical 
indication of these genes has been made apparent because of their immediate relevancy to 
individual susceptibility to CNI nephrotoxicity. Clinical application of these genes, not in 
absolute term but in the relation to the etiology and pathological mechanisms of CNI 
nephrotoxicity in kidney transplant patients, is significant, however, limited due to the 
challenging clinical presentation of toxicities induced by CNI.  
In clinical practice, conventional parameters such as drug plasma level, creatinine 
level, and estimated GFR fail to predict either rejection or toxicity because of the drug‟s 
narrow therapeutic window and low correction between dose-toxicity (26,35). The 
current standard diagnosis of CNI nephrotoxicity is largely relied on histological 
assessment using the revised Banff ‟07 criteria (7). However, CNI nephrotoxicity patho-
morphological representations have poor reproducibility, which could be subjective and 
interfered by tissue heterogeneity as well as pathologist‟s expert prejudice (20,21).  
Since lacking a defined differential diagnosis of CNI nephrotoxicity undermines 
the effectiveness of the current therapeutic monitoring effort and strategies for patient 
treatment, our study was aimed to establish molecular profiles unique to CNI 
nephrotoxicity. Microarray data collected from CNI nephrotoxicity kidney tissues of 27 
kidney transplant recipients was analyzed in the context of biological functions and gene 
interactions, using normal allograft as the control group.  
Top biological networks based on score in CNI population was associated with a 
wide range of biological functions such as metabolic disease, cellular development, renal 
 53 
necrosis, apoptosis cell-death, immunological disease, inflammatory disease, and many 
others. It underlined the multifaceted nature of calcineurin inhibitor nephrotoxicity and 
the fact that calcineurin has various physiological substrates, beside NFAT, in immune 
and non-immune cells.  
Survey of genes in cell death, renal necrosis/cell death, and cellular assembly and 
organization (network 4) revealed an up-regulation of multiple transcription regulators 
such as BCL6, ZNF24, PYCARD in contrary to a down-regulation of transcription 
regulator CLOCK. Over-expression of BAX, BCL2 associated X protein, observed in 
network 4 demonstrated the involvement of mitochondrial destruction in apoptosis cell 
death pathway of CNI nephrotoxicity as suspected in previous research studies. The 
proposed mechanism concerned the binding of cyclosporine A to cyclophilin D, a unique 
mitochondrial isoform of cyclophilin in mammals, which led to detachment of 
cyclophilin-D from mitochondrial membrane causing permeability of the transition pore 
(42). BAX is known for its molecular function in release of cytochrome c from 
mitochondria and activation of caspase activity by cytochrome c. This finding carried on 
the impact of non-immunological interactions of CNI in cells.  
Gene expression patterns of molecules in interaction network of hematological 
disease, immunological disease, and inflammatory disease (network 8) depicted negative 
regulation of many G-coupled proteins but a noticeable increase in expression of 
regulator of G-protein signaling1 (RGS1, p = 9.87E-04). The deregulation pattern of 
RGS1, among the three final gene candidates of this study, was investigated in CNI group 
for its potential value as a biomarker. RGS1 was found to play an important role in 
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multiple cellular processes including negative regulation of signal transduction and 
immune response (54).  
In vitro and in vivo studies of human RGS1 mRNA in isolated T lymphocytes 
indicated that an over-expression of this gene, especially in subset of host T cells with 
regulatory function or Treg, was essential in immunology tolerance (54,56). As Treg is 
known to play an important role in suppressing the activation of immune response and 
has been found to be inhibited by CNIs, with the possible mechanism via suppression of 
IL2 production and signal transduction. (54-57).  Analyses on proliferation and activation 
of Treg in kidney allograft treated with immunosuppressive agents, furthermore, showed 
that population of Treg in allograft treated with CsA-based in compared with sirolimus-
based regimen is significantly lower (55,57).  
Quantitative validation of RGS1 with real-time PCR, furthermore, upheld the 
synergistic relationship of the up-regulation of this gene and the disease course of CNI 
nephrotoxicity. However, contrary to our previous finding that RGS1 was only detected 
in CNI group with a significant p value and fold change, a differential expression of 
RGS1 level was also detected in IF/TA group when compared to normal allograft. mRNA 
RGS1 was  expressed at a much higher fold change in IF/TA group and in the same 
positive direction as observed in CNI group. This finding suggests the possible 
involvement of RGS1 in the pathway that CNI nephtoroxicity progresses to the 
development of IF/TA.  
Identification of the top canonical pathways by IPKB emphasized on oxidative 
stress response mediated by NRF2, 14-3-3 signaling pathway, p53 signaling pathway, 
TGF- signaling pathway, etc. Transforming growth factor-β singling pathway is known 
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to regulate multiple cell processes including proliferation, apoptosis, extracellular matrix 
production, and differentiation (41). Literature reviews reported that an up-regulation of 
TGF- signaling pathway is one of the major mechanisms that CNI nephrotoxicity 
progresses into chronic condition. (41) In particular, an over-expression of this molecular 
pathway causes epithelial messenchymal transition, a condition in which renal tubular 
epithelial cells lose their cell morphology and acquire new characteristic features of 
messenchyme, and therefore destruct basal membrane (41).  
Annotation of CNI nephrotoxicity dataset when compared with normal allograft 
showed synergic patterns of several important genes of TGF- signaling pathway such as 
Type II receptor, TAK1, Smurf 1, GRB2, Ras, cJun, AP1, and TGIF and antagonistic 
patterns of VDR and JNK, just to name a few. Genetic behavior of TGF-induced factor 
homeobox 1, or TGIF1 (p=1.22E-04), was observed along with the other two potential 
biomarkers (RGS1 and CXCR4) in our study because of its co-suppression activity on 
smad2, an important transcription factor that, in various research studies including mouse 
and human models, was believed to module fibrogenesis. In fact, interference of smad2-
dependent TGF-β signaling pathway causes an accumulation of extracellular matrix, the 
main mechanism of renal interstitial fibrosis (58-61).  
Investigation on the mechanism of action that TGIF1 involved in TGF-β signaling 
pathway revealed that TGIF1 has been found to inhibit transcriptional activation by 
smads but not repress TGF-β induced signals (IPA) (58,60). It was also emphasized that 
upon activation, smad2 forms complex with other smad proteins and translocates to 
nucleus via interaction with not only co-repressors but also co-activators (60). Although 
it presented, based on microarray data of our study, a 2.132 fold change over expression 
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of TGIF1 in kidney allograft diagnosed with CNI nephrotoxicity, validation step reported 
TGIF1 expression level was not statistically significant emough between sample groups 
to be considered as a potential gene for further study. 
It has been acknowledged that long-term exposure to calcineurin inhibitor 
progresses to the development of Interstitial Fibrosis and Tubular Atrophy, but the 
specific insights of such disease advancing mechanism is still uncharacterized. Pair-wise 
comparisons between CNI and IF/TA, with normal allograft as control, were done on the 
basis of biological function analysis and toxicology profiles. Pathology of IF/TA was 
characterized more with the involvement of renal necrosis and cell death as according to 
the top five canonical pathway analyses compared between the two groups. Molecular 
pathways that are involved in response to injury and inflammation such as NRF2-
mediated oxidative stress response, p-53 signaling pathway, and TGF- signaling 
pathway played a less important role in the complication of IF/TA as seen in the drug-
induced toxicities.  
Among the differentially expressed genes between the pathological groups of CNI 
and IF/TA, Chemokine (C-X-C motif) receptor 4 (CXCR4, p=7.18E-05) was particularly 
selected to study due to its identified interaction with cyclophilin A, which is the 
ubiquitous cellular receptor of cyclosporine (62). Experimental data showed that 
cyclophilin A might regulate the cascade signal events mediated by CXCR4 necessary in 
T cells in various physiological and pathological conditions including human 
immunodeficiency virus infection and cancer metastasis (62,63). This signal event was 
terminated when cell was treated with cyclosporine A (62).  
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Furthermore, in addition to its role in p38-dependent T cell apoptosis, according 
to microarray analysis, CXCR4‟s significant fold change found in CNI vs. NA group 
(3.328) and in IF/TA vs. NA group (21.57) indicated a computational predicted target 
relationship via statistical correlation and biological significance, which can be used to 
portray the progression of nephrotoxicity to chronic allograft dysfunction in kidney 
tissues (63). Q-PCR validation of data only reported statistical significance of mRNA 
expression level of this gene in IF/TA allograft when compared to normal allograft. 
However, the significant fold changes of this gene in CNI and IF/TA groups, calculated 
with results yielded from qPCR validation, might indicate that high expression level of 
CXCR4 and consequence of its downstream effect could possibly a contributing factor to 
the progression of CNI nephrotoxicity to IF/TA.  
Initially, we were aimed to validate the identified differentially expressed genes of 
this study in an independent validation set, based on an independent population of kidney 
transplantation. In other words, real-time PCR was supposed to be done only on the 
kidney tissues that were not been used for microarray analysis to eliminate the influence 
of environmental factor as well as other factors contributed by donor‟s age, graft quality, 
patient‟s health status, etc. However, we weren‟t able to find a large enough number of 
kidney transplant recipients to separate the samples into considerable groups for 
confirmation and validation of the microarray data. We were, instead, able to confirm and 
validate the microarray data using a combined population of kidney tissues, some of 
which were previously used for microarray analysis and kidney tissues that had not been 
used for microarray analysis.  
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As this indicated, in order to validate either diagnosis or prediction power of 
RGS1 and CXCR4, future studies are necessary to prospectively assess the marker 
sensitivity and specificity in a larger sample size. Research direction should consider 
analyzing ontology and interaction of proposed genes in a population of kidney-
transplant recipients with multiple pathologies (IF/TA, acute rejection, post-
tranplantation virus infection, etc.) in addition to CNI nephrotoxicity and using the aid of 
appropriate statistical models. The outcome with further validation should offer the 
potential of stratifying CNI nephrotoxicity to directly quantify the extent of individual 
immune response toward allograft and develop more effective immunosuppresion 
strategies by possibly optimizing the benefit to risk ratio of drug treatment.  
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